Digital medicine developer ResApp Health has announced its second clinical trial program in Perth as it seeks to accelerate the testing of its smartphone-based diagnosis of respiratory disease.
Perth-based biotech company ResApp Health had a steady first day of trade on the ASX today, after being acquired by Narhex Life Sciences in an $11 million backdoor listing.
Narhex Life Sciences has launched a $4 million capital raising to support development of a phone app that can diagnose illness by analysing the sound of a cough.
The number of backdoor listings or reverse takeovers in Western Australia is likely to rise after a change in ASX policy has simplified the process for emerging companies to access capital via existing entities.
A Perth based digital healthcare startup, ResApp Diagnostics has signed a heads of agreement to be fully acquired by Adam Sierakowski's Narhex Life Sciences.
